Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians

• Status: Not yet recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this works is to investigate the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ain Shams University
• Treatments: Indapamide

Criteria

Inclusion Criteria:

• Subjects should be healthy adult volunteers with age between (18-45) with normal body weight.

• The volunteers will be asked to provide a complete medical history, and complete a physical examination, laboratory tests (hematology, clinical chemistry, urinalysis, serology (including hepatitis B surface antigen, anti-hepatitis C virus and antihuman immunodeficiency virus antibody)

Exclusion Criteria:

• Treatment with any known enzyme -inducing /inhibiting agent within 30 days prior to the start of the study and throughout the study.

• Subjects who have taken any medication less than two weeks of the trials starting date

• Susceptibility to allergic reaction to study drugs

• Any prior surgery of the gastrointestinal tract that may interfere with drug absorption

• Gastrointestinal diseases

• Renal diseases

• Pancreatic disease including diabetes

• Hepatic diseases

• Hematological diseases or pulmonary diseases

• Abnormal laboratory values

• Subject who have donated blood or who have been involved in multiple dosing study requiring a large volume of blood (more than 500 ml) to be drawn within 6 weeks preceding the start of the study.